Twitter Beğeni Hilesi

MannKind Corporation will release its 2024 first quarter financial results and will host a conference call to discuss updates at 5pm ET on Wednesday, May 8. Those interested in listening may do so by visiting the Company’s website at: bit.ly/3NgKgEU. #MNKD

MannKind Corporation (Nasdaq: MNKD) reported its financial results for the quarter ended March 31, 2024. The webcast replay will be available on the Company website for 14 days. For the link to the replay and accompanying press release, please visit: investors.mannkindcorp.com.

Happy Mother’s Day to all the incredible moms out there! Your strength and sacrifices help to shape our world every day. We hope you enjoy your special day!

MannKind heads to San Diego this week beginning with a stop at the 2024 NTM & Bronchiectasis Patient Conference to visit with patients, families, and caregivers about developments for the potential treatment of NTM. Our pulmonary team will be at Booth# 6. See you soon! #NTMir

It’s almost time for #ATS2024 and #RIS2024! MannKind is looking forward to seeing the American Thoracic Society (ATS) in San Diego soon. Come visit with our pulmonary team at Booth #CT3 to learn more about all the developments in our orphan lung pipeline. bit.ly/3Wio8lg #MNKD #Pulmonary

When the green flag flies on the Indy 500, MannKind will be cheering on the No. 24 DRR/Cusick Motorsports car with Conor Daly – who is living with type 1 diabetes – behind the wheel. Tune in Sunday to see who will drink the milk. #MannKind #Diabetes #T1D #Indy500 Conor Daly

On this Memorial Day, we take a moment to reflect on the brave men and women who gave their lives for our country. Their courage and sacrifice will never be forgotten.

Happy Father's Day from all of us! Your dedication and guidance inspire us every day. Enjoy your well-deserved celebration!

MannKind is excited for results from the INHALE-3 study to be presented Saturday, June 22 during a 90-minute Symposium at #ADASciSessions from Dr. Irl B. Hirsch and the investigational team and moderated by Dr. Roy W. Beck. We hope to see you there beginning at 8:00 a.m. (ET).

We’re heading to the #ADASciSessions and look forward to connecting with you! Visit with MannKind and its Clinical Education Team to learn more about inhaled insulin and our latest developments in the management of diabetes. Visit us in in the Exhibit Hall at Booth# 1307.

MannKind is excited to share positive 17-week results from the INHALE-3 study presented at the American Diabetes Association’s 84th Scientific Sessions in Orlando. Study proves inhaled insulin is as effective as usual care. bit.ly/3zeRJTe #MannKind #ADASciSessions #T1D

Looking forward to the 7th World Bronchiectasis Conference, July 4-6. MannKind is proud to be an industry partner of #WBConf24 and present a poster on Clofazimine Inhalation Suspension for the treatment of NTM Pulmonary Disease. #MannKind #NTM #NTMlungDisease #LungDisease

From all of us at MannKind Corporation, Happy Independence Day! Today, we commemorate the strength & resilience that define our great nation. May your Fourth of July be filled with laughter, love & unforgettable moments with friends & family. #HappyFourth #4thOfJuly #celebrate

MannKind welcomed Danbury Mayor Roberto Alves today to tour the Connecticut site that manufactures innovative therapeutic products. Sharing what we are doing to help patients living with endocrine and orphan lung diseases are special moments in our books. #MNKD #DanburyCT

On #NationalInternDay MannKind would like to celebrate the 19 outstanding interns across our Danbury and Westlake Village sites. We are amazed to see what they have achieved within the laboratory, corporate offices, and through their community volunteer work. #MannKind

MannKind Corporation will release its 2024 second quarter financial results and will host a conference call to discuss updates at 9 am ET on Wednesday, August 7. Those interested in listening may do so by visiting the Company’s website at: bit.ly/3NgKgEU. #MNKD

We’re heading to #ADCES24 August 9-12 in New Orleans and look forward to connecting with you! Visit with MannKind and its Clinical Education Team to learn more about inhaled insulin and our latest developments in the management of diabetes. Visit us: Exhibit Hall B – Booth #937.

MannKind Corporation (Nasdaq: MNKD) reported its financial results for the quarter ended June 30, 2024. The webcast replay will be available on the Company website for 90 days. For the link to the replay and accompanying press release, please visit: investors.mannkindcorp.com.

We’re excited to speak at the 8thAnnual IPF Summit in Boston, August 21-22, on “Building a Novel Dry Powder Delivery Platform & Applications in IPF.” MannKind is progressing a Phase 1 study with Nintedanib DPI for pulmonary fibrotic diseases starting with IPF. #MNKD @ipf-summit

It’s national 401K day today! MannKind offers a 5% employer match on 401k contributions and diverse investment options for personalized retirement plans. To learn more about our total rewards package and open careers visit our website! bit.ly/397XvcI #MannKind #401kDay